Drug intelligence / Profile preview

beta variant vaccine

Development stage: Unknown
Lead developer: Gritstone Oncology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal, Oral, Sublingual, Subcutaneous

Overview

The beta variant vaccine is a COVID-19 vaccine candidate developed by Gritstone bio, specifically designed to target the SARS-CoV-2 Beta variant. It is likely a self-amplifying mRNA (samRNA) vaccine, a technology Gritstone bio is utilizing for its COVID-19 vaccine candidates. The Coalition for Epidemic Preparedness Innovations (CEPI) has provided funding to Gritstone bio to support preclinical activities and Phase 1 trials for this vaccine candidate. Its primary purpose is to induce an immune response against the Beta variant of the virus.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on beta variant vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta variant vaccine.

Explore the full profile